Your browser doesn't support javascript.
loading
All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era.
Stagg, Helen R; Flook, Mary; Martinecz, Antal; Kielmann, Karina; Abel Zur Wiesch, Pia; Karat, Aaron S; Lipman, Marc C I; Sloan, Derek J; Walker, Elizabeth F; Fielding, Katherine L.
Affiliation
  • Stagg HR; Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Flook M; Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Martinecz A; Department of Biology, Pennsylvania State University, University Park, PA, USA.
  • Kielmann K; Center for Infectious Disease Dynamics, Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA, USA.
  • Abel Zur Wiesch P; Department of Pharmacy, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
  • Karat AS; The Institute for Global Health and Development, Queen Margaret University, Musselburgh, UK.
  • Lipman MCI; Department of Biology, Pennsylvania State University, University Park, PA, USA.
  • Sloan DJ; Center for Infectious Disease Dynamics, Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA, USA.
  • Walker EF; These authors contributed equally.
  • Fielding KL; The Institute for Global Health and Development, Queen Margaret University, Musselburgh, UK.
ERJ Open Res ; 6(4)2020 Oct.
Article in En | MEDLINE | ID: mdl-33263043
ABSTRACT
Adherence to treatment for tuberculosis (TB) has been a concern for many decades, resulting in the World Health Organization's recommendation of the direct observation of treatment in the 1990s. Recent advances in digital adherence technologies (DATs) have renewed discussion on how to best address nonadherence, as well as offering important information on dose-by-dose adherence patterns and their variability between countries and settings. Previous studies have largely focussed on percentage thresholds to delineate sufficient adherence, but this is misleading and limited, given the complex and dynamic nature of adherence over the treatment course. Instead, we apply a standardised taxonomy - as adopted by the international adherence community - to dose-by-dose medication-taking data, which divides missed doses into 1) late/noninitiation (starting treatment later than expected/not starting), 2) discontinuation (ending treatment early), and 3) suboptimal implementation (intermittent missed doses). Using this taxonomy, we can consider the implications of different forms of nonadherence for intervention and regimen design. For example, can treatment regimens be adapted to increase the "forgiveness" of common patterns of suboptimal implementation to protect against treatment failure and the development of drug resistance? Is it reasonable to treat all missed doses of treatment as equally problematic and equally common when deploying DATs? Can DAT data be used to indicate the patients that need enhanced levels of support during their treatment course? Critically, we pinpoint key areas where knowledge regarding treatment adherence is sparse and impeding scientific progress.

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: ERJ Open Res Year: 2020 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: ERJ Open Res Year: 2020 Type: Article Affiliation country: United kingdom